Innovative Glycopolymer Technology Platform

Improving the treatment of mucosal and dermal diseases with the power of glycopolymers

Targeted Therapies to Protect, Restore, and Repair the Body

Targeted therapies

Rapid bench-to-bedside translation

Excellent safety profiles

Scalable GMP production

Protecting the gastrointestinal (GI) tract from cancer therapy

Side effects of radiation and chemotherapy include gut epithelial cell death and gut barrier damage, known as GI mucositis. Synedgen is developing first-in-class cancer adjunctive therapeutics to repair GI mucositis injury, promote healing, and restore a healthy microbiome. Our lead drug, SYGN305, is being developed to help patients tolerate cancer therapy by managing acute GI side effects and preventing lasting damage to the GI tract.